vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $766.5M, roughly 1.6× SCANSOURCE, INC.). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 2.2%, a 14.8% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs 2.5%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $28.9M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 0.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
JAZZ vs SCSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $766.5M |
| Net Profit | $203.5M | $16.5M |
| Gross Margin | — | 13.4% |
| Operating Margin | 21.2% | 2.3% |
| Net Margin | 17.0% | 2.2% |
| Revenue YoY | 10.1% | 2.5% |
| Net Profit YoY | 6.5% | -3.3% |
| EPS (diluted) | $3.34 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $766.5M | ||
| Q3 25 | $1.1B | $739.6M | ||
| Q2 25 | $1.0B | $812.9M | ||
| Q1 25 | $897.8M | $704.8M | ||
| Q4 24 | $1.1B | $747.5M | ||
| Q3 24 | $1.1B | $775.6M | ||
| Q2 24 | $1.0B | $746.1M | ||
| Q1 24 | $902.0M | $752.6M |
| Q4 25 | $203.5M | $16.5M | ||
| Q3 25 | $251.4M | $19.9M | ||
| Q2 25 | $-718.5M | $20.1M | ||
| Q1 25 | $-92.5M | $17.4M | ||
| Q4 24 | $191.1M | $17.1M | ||
| Q3 24 | $215.1M | $17.0M | ||
| Q2 24 | $168.6M | $16.1M | ||
| Q1 24 | $-14.6M | $12.8M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 12.6% |
| Q4 25 | 21.2% | 2.3% | ||
| Q3 25 | 5.1% | 3.5% | ||
| Q2 25 | -65.6% | 3.3% | ||
| Q1 25 | -6.2% | 3.2% | ||
| Q4 24 | 17.5% | 2.5% | ||
| Q3 24 | 24.7% | 2.3% | ||
| Q2 24 | 19.5% | 2.9% | ||
| Q1 24 | 7.3% | 2.3% |
| Q4 25 | 17.0% | 2.2% | ||
| Q3 25 | 22.3% | 2.7% | ||
| Q2 25 | -68.7% | 2.5% | ||
| Q1 25 | -10.3% | 2.5% | ||
| Q4 24 | 17.6% | 2.3% | ||
| Q3 24 | 20.4% | 2.2% | ||
| Q2 24 | 16.5% | 2.2% | ||
| Q1 24 | -1.6% | 1.7% |
| Q4 25 | $3.34 | $0.75 | ||
| Q3 25 | $4.08 | $0.89 | ||
| Q2 25 | $-11.74 | $0.87 | ||
| Q1 25 | $-1.52 | $0.74 | ||
| Q4 24 | $2.97 | $0.70 | ||
| Q3 24 | $3.42 | $0.69 | ||
| Q2 24 | $2.49 | $0.66 | ||
| Q1 24 | $-0.23 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $83.5M |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $910.9M |
| Total Assets | $11.7B | $1.7B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $83.5M | ||
| Q3 25 | $1.3B | $124.9M | ||
| Q2 25 | $1.2B | $126.2M | ||
| Q1 25 | $1.9B | $146.3M | ||
| Q4 24 | $2.4B | $110.5M | ||
| Q3 24 | $2.2B | $145.0M | ||
| Q2 24 | $1.4B | $185.5M | ||
| Q1 24 | $1.4B | $159.1M |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $910.9M | ||
| Q3 25 | $4.0B | $914.0M | ||
| Q2 25 | $3.7B | $906.4M | ||
| Q1 25 | $4.2B | $901.7M | ||
| Q4 24 | $4.1B | $900.7M | ||
| Q3 24 | $4.2B | $920.9M | ||
| Q2 24 | $3.8B | $924.3M | ||
| Q1 24 | $3.7B | $944.1M |
| Q4 25 | $11.7B | $1.7B | ||
| Q3 25 | $11.4B | $1.7B | ||
| Q2 25 | $10.9B | $1.8B | ||
| Q1 25 | $11.5B | $1.7B | ||
| Q4 24 | $12.0B | $1.7B | ||
| Q3 24 | $12.3B | $1.8B | ||
| Q2 24 | $11.4B | $1.8B | ||
| Q1 24 | $11.3B | $1.8B |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $30.8M |
| Free Cash FlowOCF − Capex | $345.8M | $28.9M |
| FCF MarginFCF / Revenue | 28.9% | 3.8% |
| Capex IntensityCapex / Revenue | 1.4% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.78× | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $30.8M | ||
| Q3 25 | $474.6M | $23.2M | ||
| Q2 25 | $88.9M | — | ||
| Q1 25 | $429.8M | $66.1M | ||
| Q4 24 | $398.6M | $-6.2M | ||
| Q3 24 | $398.7M | $44.8M | ||
| Q2 24 | $331.4M | — | ||
| Q1 24 | $267.2M | $160.2M |
| Q4 25 | $345.8M | $28.9M | ||
| Q3 25 | $459.4M | $20.8M | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $415.9M | $64.6M | ||
| Q4 24 | $385.3M | $-8.2M | ||
| Q3 24 | $388.0M | $42.5M | ||
| Q2 24 | $324.3M | — | ||
| Q1 24 | $260.3M | $157.7M |
| Q4 25 | 28.9% | 3.8% | ||
| Q3 25 | 40.8% | 2.8% | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 46.3% | 9.2% | ||
| Q4 24 | 35.4% | -1.1% | ||
| Q3 24 | 36.8% | 5.5% | ||
| Q2 24 | 31.7% | — | ||
| Q1 24 | 28.9% | 21.0% |
| Q4 25 | 1.4% | 0.3% | ||
| Q3 25 | 1.3% | 0.3% | ||
| Q2 25 | 1.2% | 0.3% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 1.2% | 0.3% | ||
| Q3 24 | 1.0% | 0.3% | ||
| Q2 24 | 0.7% | 0.2% | ||
| Q1 24 | 0.8% | 0.3% |
| Q4 25 | 1.78× | 1.87× | ||
| Q3 25 | 1.89× | 1.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | 2.09× | -0.36× | ||
| Q3 24 | 1.85× | 2.64× | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
